Acadian Asset Management LLC Has $2.42 Million Stake in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Acadian Asset Management LLC reduced its stock position in Alnylam Pharmaceuticals by 46.2% in the first quarter, resulting in ownership of 8,977 shares worth approximately $2.42 million.
• Alnylam Pharmaceuticals received multiple price target upgrades from analysts, with Evercore ISI raising their target to $515.05 and JPMorgan Chase to $475.00, indicating strong market confidence.
• The company reported $0.32 earnings per share for the last quarter, exceeding expectations and achieving a year-over-year revenue increase of 17.3%.

Acadian Asset Management LLC trimmed its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 46.2% in the first quarter, according to its most recent filing with the SEC. The firm owned 8,977 shares of the biopharmaceutical company's stock after selling 7,699 shares during the period. Acadian Asset Management LLC's holdings in Alnylam Pharmaceuticals were worth $2,421,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ALNY. SVB Wealth LLC bought a new position in shares of Alnylam Pharmaceuticals during the 1st quarter worth about $27,000. Park Square Financial Group LLC bought a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $28,000. Whipplewood Advisors LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 208.8% during the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 71 shares during the period. Bessemer Group Inc. lifted its holdings in Alnylam Pharmaceuticals by 176.9% during the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 69 shares during the last quarter. Finally, Washington Trust Advisors Inc. lifted its holdings in Alnylam Pharmaceuticals by 53.5% during the 1st quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company's stock valued at $47,000 after purchasing an additional 61 shares during the last quarter. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock traded up $1.39 during trading hours on Friday, reaching $453.56. 1,713,315 shares of the stock were exchanged, compared to its average volume of 1,073,061. The company has a market cap of $59.45 billion, a P/E ratio of -183.63 and a beta of 0.32. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $484.21. The stock has a 50 day moving average of $415.05 and a two-hundred day moving average of $324.19.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.54) by $0.86. The firm had revenue of $773.69 million for the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The business's revenue for the quarter was up 17.3% on a year-over-year basis. During the same period in the prior year, the company posted ($0.13) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In related news, Director Colleen F. Reitan sold 18,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $467.60, for a total value of $8,416,800.00. Following the completion of the transaction, the director owned 775 shares in the company, valued at $362,390. This trade represents a 95.87% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Yvonne Greenstreet sold 6,979 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $453.27, for a total transaction of $3,163,371.33. Following the completion of the transaction, the chief executive officer owned 56,221 shares of the company's stock, valued at approximately $25,483,292.67. This trade represents a 11.04% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 75,594 shares of company stock valued at $33,968,256. 1.50% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities analysts recently issued reports on ALNY shares. JPMorgan Chase & Co. lifted their price target on shares of Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the company an "overweight" rating in a report on Wednesday, August 6th. Truist Financial initiated coverage on shares of Alnylam Pharmaceuticals in a research note on Monday, July 21st. They issued a "buy" rating and a $385.00 target price for the company. Morgan Stanley lifted their price target on shares of Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the stock an "equal weight" rating in a research report on Friday, August 1st. Barclays lifted their price target on shares of Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the stock an "overweight" rating in a research report on Friday, August 1st. Finally, Chardan Capital boosted their price objective on shares of Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the company a "buy" rating in a report on Friday, August 1st. Twenty-four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $439.58.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.